Introduction
Accurately predicting risk of mortality or hospitalization owing to heart failure (HF) in patients with HF might lead to intensified monitoring and treatment 1 -8 and help physicians, nurses and patients in making better management decisions. 9 In addition, selecting high-risk patients in phase III drug and device trials may enrich clinical event rates and decrease sample size.
Many risk prediction models for patients with HF have been published. 10 Of 117 models included in a recent meta-analysis, only 33% were validated in a separate cohort. Most of these models performed only moderately (c-statistic values 0.71, 0.63, and 0.68, for mortality, HF hospitalization or their composite, respectively).
10 -14 Patient data in these models were derived predominantly from randomized controlled intervention trials, which enrol highly selected and motivated patients who volunteer for research, or from administrative datasets, such as medical insurance claims, that often have diagnostic inaccuracies and fail to record key clinical data such as blood pressure or a measure of renal function.
BIOSTAT-CHF is a large European project that was specifically designed to develop and validate risk prediction models in patients with HF. 15 In the present report we provide the principal findings of this study.
Methods
The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) recommendation was used as a guideline in developing and validating our prediction models.
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Patient index and validation cohort
Our models were developed using data from the BIOSTAT-CHF cohort. 15 In brief, BIOSTAT-CHF enrolled an index cohort of 2516 patients from 69 hospital centres in 11 European countries predominantly during 2010-2014 and a comparable validation cohort of 1738 patients from six centres in Scotland, UK, enrolled predominantly during 2010-2014. Patients were enrolled as inpatients or from outpatient clinics. The median follow-up in each cohort was 21 months with an interquartile range of 15 months and 27 months.
Patients from the index cohort were aged >18 years with symptoms of new-onset or worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or B-type natriuretic peptide (BNP) and/or N-terminal pro-B-type natriuretic peptide (NT-proBNP) plasma levels >400 pg/mL or >2000 pg/mL, respectively, treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. BIOSTAT-CHF was also designed to establish the effects of and response to initiation and uptitration of and response to guideline directed medical therapy. Therefore, in order to be considered for enrolment in either cohort, patients had either not to be treated with an angiotensin-converting enzyme (ACE)-inhibitor/angiotensin receptor blocker (ARB) and/or beta-blocker or had to be treated with ≤50% of target doses of these therapies at the time of inclusion, and with an anticipated initiation or uptitration of such therapy by the treating physician.
Patients from the validation cohort were aged >18 years with a HF diagnosis based on echocardiographic evidence of left ventricular (LV) During follow-up, patients underwent a second visit at 9 months after inclusion. Every 6 months, patients were contacted, usually by telephone, to collect information on medication and clinical events.
Outcomes and predictor variables
Primary outcomes were time to all-cause mortality, first HF hospitalization and the composite outcome of all-cause mortality and HF hospitalization.
Using a Cox proportional hazards model, we evaluated the predictive value of 42 demographic, clinical and biochemical variables that were measured at inclusion. These variables were selected, because previous studies identified those factors to be associated with mortality and hospitalization. An overview of the predictor variables and summary statistics are available in the Supplementary material online, Table S1 .
Non-linearity of the log-hazard for variables with quantitative values was evaluated using restricted cubic splines. 17 For the non-linear variables, transformations to linearity were applied (e.g. log-transformation or square root) and re-tested using cubic splines. The proportional hazards assumption of the Cox model was assessed using Schoenfeld residuals and the Therneau and Grambsch non-proportionality test. 18 Missing predictor values were imputed using multichain Monte Carlo methods with Gibbs sampling. We used the R-package 'mice'. 19 We imputed missing data five times, performed the analysis over all five imputations and averaged results using Rubin's rules. 19
Model development
We conducted stepwise backward regressions on the predictor variables by Akaike information criterion (AIC) in 1000 bootstrap samples for each imputation set. 20 We chose variables for our full model when predictor variables were selected in more than 40% of all 5 × 1000 bootstrap samples. In addition, to make our models more applicable in medical practice, we developed a reduced compact model with a maximum of five predictor variables in the mortality and HF hospitalization models and 10 in the composite model. Variables selected in the compact model were used to develop a simplified risk score, using a decision tree algorithm, 21 and calculated survival probabilities using Cox regression for all three outcomes.
Model validation
We first validated our models internally correcting the raw c-statistic 22 for optimism by 1000 bootstrap sampling in the five imputation sets. We used the procedure suggested by Musoro et al. 23 Second, we validated our models externally in the validation cohort data. For all patients in this cohort we calculated the risk score using the Cox regression weights estimated from the index cohort and subsequently calculated the c-statistic for the validation cohort. The distribution of prediction scores in the index cohort were then compared with the distribution of those from the validation cohort. We also applied two prediction models-the Seattle Heart Failure Model (SHFM) 24 and the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) 25 mortality scores-with the BIOSTAT-CHF cohort and compared c-statistic values with our developed models. In addition, we compared c-statistic values in our models for patients with either HF with reduced (HFrEF) or preserved ejection fraction (HFpEF) in the index and validation cohorts.
Results
Patients in the index cohort (n = 2516) had a mean (±SD) age of 69 (±12) years, 27% were female, 83% were in New York Heart Association (NYHA) class II-III with a mean (±SD) LVEF of 31 (±11)%, and 162 (7%) had a LVEF > 45%. Further details were previously published, 15 and baseline characteristics of both cohorts are described in the Supplementary material online, validation cohort (n = 1738) had a mean (±SD) age of 74 (±11) years, 34% were female, 85% were in NYHA class II-III with a mean (±SD) LVEF of 41 (±13)%, and 529 (34%) had a LVEF >45%. 15 Most patients in this cohort were enrolled as outpatients (46%). During a median follow-up of 21 (IQR 11-32) months, 589 (34%) patients died and 610 (35%) were hospitalized for worsening HF, and 894 (51%) had a first event of either death or HF hospitalization.
Model development in the index cohort
Full models
The proportional hazards assumption for the linear effect of the variables on mortality, HF hospitalization risk, and the risk of the composite outcome was applicable to all variables. The final full models included those variables that appeared in >40% of the bootstrap analyses (see the Supplementary material online, Figure S1 ), which for mortality consisted of 16 variables ( Table 1) and yielded a raw c-statistic of 0.73 (0.73 after correction for optimism). The relation of each variable with the outcome variables are presented in the Supplementary material online, Table S2 . The final full model to predict HF hospitalization incorporated 10 variables, which achieved a raw c-statistic of 0.69 (0.68 after correction for optimism). The final full model to predict the composite outcome consisted of 15 variables, which had a raw c-statistic of 0.71 (0.70 corrected for optimism).
Compact models
The final compact mortality model included five variables that appeared in more than 70% of the bootstrap analyses ( Table 2) . More advanced age, higher blood urea nitrogen (BUN) and NT-proBNP, lower haemoglobin and failure to prescribe a beta-blocker predicted a higher mortality with a raw c-statistic of 0.69 (0.69 after correction for optimism increased risk of HF hospitalization with a raw c-statistic of 0.67, and 0.66 after correcting for optimism ( Table 3) . The final compact model to predict the combined endpoint included nine variables that appeared in more than 70% of the bootstrap analyses. More advanced age, HF hospitalization in the year before inclusion, presence of oedema, higher NT-proBNP, lower SBP, haemoglobin, high-density lipoprotein (HDL) levels, serum sodium concentration, and failure to prescribe a beta-blocker predicted the composite outcome with a raw and optimism corrected c-statistic value of 0.69.
Point score model
For the risk score we used the variables from the compact model. The decision tree algorithm selected the following cut-off points for optimal classification: NT-proBNP >4000 pg/mL, BUN >11 mmol/L, HDL <1.05 mmol/L, age >70 years, sodium <140 mmol/L, haemoglobin <12 g/dL, eGFR (CKD-EPI formula) <40 mL/min, and SBP <140 mmHg. A score for each patient was subsequently calculated by adding one point for each 'adversely' affected variable, resulting in a score range of 0-5, 0-5, and 0-9, for mortality, HF hospitalization, and the combined endpoint, respectively. Kaplan-Meier survival curves for each score were then calculated (Figure 1) . The risk scores can be calculated using the online calculator available at: http://www .biostat-chf.eu In the validation cohort, the c-statistic for the full models were 0.73, 0.64, and 0.68 for mortality, HF hospitalization, and their composite, respectively, and 0.72, 0.61, and 0.67 for the compact models. The 2-year event rates for risk scores were almost uniformly higher in the validation cohort (Figure 1) . Calibration plots are presented in the Supplementary material online, Figures S2  and S3 .
Applying the SHFM and MAGGIC mortality scores to our cohort achieved a similar c-statistic (0.68) to the BIOSTAT compact model. 
Difference between heart failure with reduced and preserved ejection fraction
Discussion
This analysis demonstrates that a small number of readily available clinical variables predict outcome consistently and with reasonable accuracy in two patient populations with symptomatic HF. Predictors of mortality were remarkably different from predictors of HF hospitalization.
We recently published a meta-analysis on all available risk prediction models in patients with HF.
10 In 117 models, 249 different . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . variables were used. The mean c-statistic across all models was 0.71, 0.63, and 0.68 for predicting mortality, HF hospitalization, or their composite, respectively. The BIOSTAT-CHF prediction model for mortality therefore performed slightly better than average. This is remarkable, as BIOSTAT-CHF included much broader and more heterogeneous populations, closer to routine clinical practice, than the populations providing the data for most other HF risk prediction models. 10 -12 We provided outcomes of both full models that included variables that appeared in more than 60% of the bootstrap analyses and compact models that included variables that appeared in more than 70% of the bootstrap analyses. An advantage of the full model is a better predictive value. Given the high number of events, the number of variables that are used in the full model was statistically allowed. Another advantage of the full model is that it does justice to the complexity of the large number of factors that determine prognosis of patients. An advantage of the compact model is that it is easier to use, but its limitations should be taken into account.
We also compared our risk scores with two other more complex models based mainly on clinical trial populations; the SHFM 24 and the MAGGIC, 25 which reported c-statistics of 0.72 and 0.74, respectively, for predicting mortality. 24, 26 When we applied the SHFM and MAGGIC scores to our BIOSTAT cohort, it yielded a similar c-statistic of 0.68 for mortality. This supports the hypothesis that our patient population is more heterogeneous, making it more difficult to achieve accurate predictions.
The majority of currently existing prognostic models in patients with HF are based on data from randomized controlled trials or extracted from administrative datasets, such as medical insurance claims. Patients selected for clinical trials are generally a highly selected group of volunteers that have few serious co-morbidities and a high disease burden. Administrative datasets often do not include the detailed medical data needed to develop accurate prediction models. BIOSTAT-CHF included a broad cohort of patients in Europe, with a very limited number of inclusion and exclusion criteria, and therefore more accurately reflects patients with HF in daily clinical practice.
Similar to many other risk prediction models, we found that the accuracy to predict mortality was moderate, but the model was less accurate at predicting HF hospitalization. This might be because worsening evidence of HF is not the sole or even dominant factor precipitating hospitalization. 27 Accordingly, no relation has been found between early readmissions and mortality after a first hospitalization.
28 -31 The variables that were included in the mortality models were different from those of HF hospitalization. The only variable included in all compact models was age. The majority of our predictors of HF hospitalization have also been described in other models. In particular, a previous HF hospitalization identifies patients at greater risk of (re)hospitalization, and was associated with a more than doubled risk of repeat HF hospitalization. 32 This variable might therefore identify an especially vulnerable patient group in which fluid balance is easily disrupted, hence causing signs and symptoms of congestion warranting admission and intravenous diuretic treatment. The finding that oedema is also a marker of increased hospitalization risk but not of mortality supports this notion and suggests that the underlying pathology might differ significantly. 33 In our mortality model, BUN was an independent predictor, while eGFR was a predictor of rehospitalizations. While BUN is one of the strongest predictors of adverse outcome in HF, the information captured by this marker is often thought to encompass more than renal function alone. 34, 35 However, eGFR and BUN are strongly correlated and this in part explains the absence of BUN in the hospitalization model and the absence of eGFR in the mortality model.
Interestingly, serum sodium and HDL levels are only included in the compact models for the combined endpoint. The inclusion of HDL in these models was not expected beforehand, yet in one report on a small population of patients with advanced HF, HDL was the strongest predictor of an adverse outcome. 36 Traditionally, HDL has been associated with the risk of atherosclerosis; however, recent evidence showed that the HDL proteome also plays an important role in inflammation. 37 Hyponatraemia is a well-recognized predictor of poor outcome in both acute and chronic HF and it is therefore not surprising that low serum sodium is associated with an increased risk of the combined endpoint. 38, 39 The use of a beta-blocker at baseline was associated with a lower risk of mortality and the combined endpoint. The inclusion of beta-blocker use in our model might be confounded by disease severity influencing tolerability of beta-blockers, creating a potential selection bias. In addition, suboptimal medical treatment was an inclusion criterion for our study. However, it may also confirm the importance of the use of beta-blockers in HF and its effect on improved outcome. Further analyses of the BIOSTAT-CHF study will attempt to resolve the determinants and clinical outcome related to inadequate uptitration of ACE-inhibitors and/or beta-blockers.
Limitations and strengths
The BIOSTAT-CHF cohort is a European multinational prospective cohort. Healthcare systems and patient treatment between the different European countries vary greatly. This might influence management, outcome, and prediction, although all investigators were encouraged to follow the recommendations of the ESC HF Guidelines. 2 However, because of the multinational character of this cohort, the results will be highly generalizable. Our validation cohort consisted only of patients from Scotland. This cohort might not resemble the heterogeneity of the European patient population. However, this cohort was a completely independent validation cohort with no ties to the index cohort. Both cohorts selected patients who were suboptimally treated with ACE-inhibitors/ARBs and/or beta-blockers, which might further limit the generalizability of the results.
Events were not adjudicated by an adjudication committee, but by the treating physicians. However, a systematic metaanalysis failed to detect any effect of event adjudication on study conclusions of cardiovascular outcome trials and the numbers of events included in the final analyses were minimally changed. 40 With regard to the hospitalization endpoint, competing risks need to be taken into account (i.e. if a patient died, he/she cannot be hospitalized any more). in both the index and validation cohorts, BIOSTAT-CHF included patients with HFrEF and HFpEF. This can be regarded as both a strength and a limitation. The HFpEF patients in the index cohort were limited to those patients with NT-proBNP levels >2000 pg/mL, thereby increasing the reliability of the diagnosis but reducing its prevalence and excluding milder cases. There were small differences in c-statistic values between HFrEF and HFpEF in the index cohort, but in the validation cohort, the prediction model performed similarly in patients with either HFpEF or HFrEF. However, given the low number of HFpEF patients in the index cohorts, these data should be interpreted carefully. Finally, the large majority of patients (99%) was Caucasian, which limits the generalizability of the models.
Conclusion
We developed and validated models for predicting mortality, HF hospitalization and the combined outcome of mortality and HF hospitalization. Variables that were included in the mortality models were remarkably different from those in the HF hospitalization models. In addition, we presented a simplified risk score for use in clinical practice. In comparison with well-known existing prediction scores, our developed models performed better in this patient population.
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Supplementary Information
Additional Supporting Information may be found in the online version of this article: Figure S1 . Percentage of bootstrap samples of each variable selected. Red and green lines are the 40% full and compact model bootstrap sample variable selection lines. Figure S2 . Calibration plot of the compact model in the index cohort. Gray is the optimal calibration, black are the uncorrected calibration lines and blue are the optimism corrected calibration lines. Figure S3 . Calibration plot of the compact model in the validation cohort. Table S1 . Description of each variable used in model development [% (number), mean (SD) or median (interquartile range)], with % and number of values missing for patients. Table S2 . Univariable analysis.
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